Literature DB >> 21605066

Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop.

Young G Shin1, Hoa Le, Cyrus Khojasteh, Cornelis E C A Hop.   

Abstract

Metabolite identification study plays an important role in determining the sites of metabolic liability of new chemical entities (NCEs) in drug discovery for lead optimization. Here we compare the two predictive software, MetaSite and StarDrop, available for this purpose. They work very differently but are used to predict the site of oxidation by major human cytochrome P450 (CYP) isoforms. Neither software can predict non-CYP catalyzed metabolism nor the rates of metabolism. For the purpose of comparing the two software packages, we tested known probe substrate for these enzymes, which included 12 substrates of CYP3A4 and 18 substrates of CYP2C9 and CYP2D6 were analyzed by each software and the results were compared. It is possible that these known substrates were part of the training set but we are not aware of it. To assess the performance of each software we assigned a point system for each correct prediction. The total points assigned for each CYP isoform experimentally were compared as a percentage of the total points assigned theoretically for the first choice prediction for all substrates for each isoform. Our results show that MetaSite and StarDrop are similar in predicting the correct site of metabolism by CYP3A4 (78% vs 83%, respectively). StarDrop appears to do slightly better in predicting the correct site of metabolism by CYP2C9 and CYP2D6 metabolism (89% and 93%, respectively) compared to MetaSite (63% and 70%, respectively). The sites of metabolism (SOM) from 34 in-house NCEs incubated in human liver microsomes or human hepatocytes were also evaluated using two prediction software packages and the results showed comparable SOM predictions. What makes this comparison challenging is that the contribution of each isoform to the intrinsic clearance (Clint) is not known. Overall the software were comparable except for MetaSite performing better for CYP2D6 and that MetaSite has a liver model that is absent in StarDrop that predicted with 82% accuracy.
© 2011 Bentham Science Publishers

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605066     DOI: 10.2174/138620711796957170

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  5 in total

1.  A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery.

Authors:  Ignacio Aliagas; Alberto Gobbi; Timothy Heffron; Man-Ling Lee; Daniel F Ortwine; Mark Zak; S Cyrus Khojasteh
Journal:  J Comput Aided Mol Des       Date:  2015-02-24       Impact factor: 3.686

2.  LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.

Authors:  Mohamed W Attwa; Ali S Abdelhameed; Adnan A Kadi
Journal:  Drug Des Devel Ther       Date:  2021-09-15       Impact factor: 4.162

3.  Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software.

Authors:  Megan L Peach; Alexey V Zakharov; Ruifeng Liu; Angelo Pugliese; Gregory Tawa; Anders Wallqvist; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2012-10       Impact factor: 3.808

4.  Galeon: A Biologically Active Molecule with In Silico Metabolite Prediction, In Vitro Metabolic Profiling in Rat Liver Microsomes, and In Silico Binding Mechanisms with CYP450 Isoforms.

Authors:  A F M Motiur Rahman; Wencui Yin; Adnan A Kadi; Yurngdong Jahng
Journal:  Molecules       Date:  2020-12-13       Impact factor: 4.411

5.  A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes.

Authors:  Mohamed W Attwa; Ali S Abdelhameed; Nawaf A Alsaif; Adnan A Kadi; Haitham AlRabiah
Journal:  RSC Adv       Date:  2022-07-13       Impact factor: 4.036

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.